Search

Displaying results 4561 - 4570 of 10000 in total
  1. Drug

    ACA 125

    go.drugbank.com/drugs/DB05489
    Investigational

    Antiidiotypic antibodies bearing the internal image of an antigen expressed on the surface of the tumor are suited to this approach. … This new concept of oncological immunotherapy consists of an attempt to trigger the immune system of the host to respond against tumor cells.

  2. Drug

    KW-7158

    go.drugbank.com/drugs/DB05498
    Experimental

    The therapeutic effects of KW-7158 in overactive bladder may be due to the activation of A-type K(+) channels which regulate afferent neuron excitability and firing properties in the dorsal root ganglion … (involuntary abnormal contraction of the bladder).

  3. Drug

    Tandospirone

    go.drugbank.com/drugs/DB12833
    Investigational

    Tandospirone has been used in trials studying the treatment of Schizophrenia.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor Agonists
  4. Drug

    Metyrapone

    go.drugbank.com/drugs/DB01011
    ApprovedInvestigational

    An inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome.

  5. Drug

    DOTMP HO-166

    go.drugbank.com/drugs/DB05380
    Experimental

    SRT is designed to be used in combination with high-dose chemotherapy producing a direct therapeutic effect on the tumor sites in the bone plus a general bone-marrow effect to destroy myeloma cells in … the bone marrow.

  6. Drug

    UCB-1184197

    go.drugbank.com/drugs/DB05092
    Investigational

    CDP323 is an antagonist of the _vascular cell adhesion molecule 1_ (VCAM-1) binding to alpha4-integrins (other adhesion molecules), a process thought to be implicated in the pathophysiology of Multiple … CDP323 was originally developed by the British biopharmaceutical company Celltech plc. (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis.

  7. Drug

    Demegestone

    go.drugbank.com/drugs/DB13857
    Experimental

    Demegestone is a progesterone receptor agonist that was previously used to treat luteal insufficiency. It was previously marketed in France as Lutionex, but has since been discontinued.

    Categories: Sex Hormones and Modulators of the Genital System
  8. Target

    Tumor necrosis factor ligand superfamily member 11

    go.drugbank.com/bio_entities/BE0003517
    TargetHumans

    Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions ...

    Synonyms: Receptor activator of nuclear factor kappa-B ligand
  9. Target

    Hepatocyte nuclear factor 4-alpha

    go.drugbank.com/bio_entities/BE0004019
    TargetHumans

    Transcriptional regulator which controls the expression of hepatic genes during the transition of endodermal cells to hepatic progenitor cells, facilitating the recruitment of RNA pol II to the promoters of target genes (PubMed:30597922)...

    Synonyms: Nuclear receptor subfamily 2 group A member 1
  10. Drug

    CCX915

    go.drugbank.com/drugs/DB05159
    Experimental

    The CCR2 receptor is thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II diabetes and atherosclerosis. … CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders.